Silence Therapeutics PLC's (LON:SLN) David Solomon speaks to Proactive London's Andrew Scott soon after announcing they've hit the first milestone in their deal with Mallinckrodt Pharmaceuticals - triggering a US$2mln research payment.
The UK specialist in RNA therapeutics has already received US$20mln upfront as part of a potential multi-million dollar collaboration announced in July.
The AIM-listed drug developer could receive up to US$10mln of research milestones and a further US$100mln in regulatory and clinical payments.
